BC Innovations | Sep 11, 2019
Translation in Brief

Cold Spring Harbor team finds off-target activity can drive antitumor effects

Drug developers may need to revise how they validate drug targets, according to a Cold Spring Harbor Laboratory study that found 10 clinical oncology candidates killed tumor cells by hitting unintended targets. The study also...
BC Innovations | Apr 10, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis In vitro and mouse studies identified a tetrahydrocarboline-based HDAC6 inhibitor that could help treat arthritis. Chemical synthesis and in vitro activity assays of tetrahydrocarboline analogs yielded a compound that inhibited HDAC6 with a...
BioCentury | Jan 27, 2018
Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
BC Innovations | Oct 24, 2017
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest inhibiting HDAC6 could help treat ALS. In ALS patient-derived motor neurons, inhibition of HDAC6 with two tool compounds or antisense oligonucleotide (ASO)-mediated knockdown decreased axon transport...
BC Week In Review | Dec 9, 2016
Company News

Acetylon, Celgene deal

Acetylon said Celgene will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston, Mass.). Celgene will gain rights to...
BC Extra | Dec 3, 2016
Company News

Celgene acquiring Acetylon after spinout of newco

Acetylon Pharmaceuticals Inc. (Boston, Mass.) said Celgene Corp. (NASDAQ:CELG) will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston,...
BC Week In Review | Dec 21, 2015
Clinical News

ACY-241: Preliminary Phase I data

Preliminary data from 7 relapsed or relapsed/refractory MM patients previously treated with >=2 cycles of Revlimid lenalidomide and a proteasome inhibitor in the open-label, U.S. Phase Ia/Ib ACE-MM-200 trial showed that once-daily oral ACY-241 on...
Items per page:
1 - 7 of 7